Mobeus Income & Growth 2 VCT plc
(the "Company")
LEI: 213800LY62XLI1B4VX35
Realisation of investment in Bourn Bioscience Limited
The Company is pleased to announce the sale of its investment in Bourn Bioscience Limited ("Bourn") on 29 December 2020 to Triangle Health Care Partners 1 LP, a Canadian Fund. The Company has received £1.00 million in cash from the sale, contributing to a realised gain over cost over the life of the investment of £0.48 million, being the equivalent of 0.66 pence per share.
Cash proceeds have been received over the life of the investment of £1.24 million, against an original cost of £0.76 million. This represents a return for the Company of 1.6 times the original investment cost and an IRR of 8.5% in the nearly seven years that this investment was held.
In isolation, the impact of this sale on the Company's latest announced NAV per share of 79.25 pence as at 30 September 2020, would be an increase of 1.01 pence per share. The Company emphasises that the increase in NAV per share from this realisation is in isolation from other changes in the Company's balance sheet, including valuation and other transaction movements in the Company's investment portfolio, that may also have affected the NAV per share since 30 September 2020.
For further information, please contact:
Mobeus Equity Partners LLP, Company Secretary 020 7024 7600
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
